This double-blind, placebo-controlled study investigated the effects of oral morphine (0, 45, 135 mg/70 kg) and oral oxycodone (0, 15, 45 mg/70 kg) on buprenorphinemaintained opioid addicts. As a 3 : 1 morphine : oxycodone oral dose ratio yielded equivalent subjective and physiological effects in nondependent individuals, this ratio was used in the present study. Two self-administration laboratory procedures -that is, a drug versus money and a drug versus drug procedure -were assessed. Study participants (N = 12) lived in the hospital and were maintained on 4 mg/day sublingual buprenorphine. When participants chose between drug and money, money was preferred over all drug doses; only high-dose oxycodone was self-administered more than placebo. When participants chose between drug and drug, both drugs were chosen more than placebo, high doses of each drug were chosen over low doses, and high-dose oxycodone was preferred over high-dose morphine. The subjective, performance-impairing, and miotic effects of high-dose oxycodone were generally greater than those of high-dose morphine. The study demonstrated that a 3 : 1 oral dose ratio of morphine : oxycodone was not equipotent in buprenorphinedependent individuals. Both self-administration procedures were effective for assessing the relative reinforcing effects of drugs; preference for one procedure should be driven by the specific research question of interest.
This double-blind, placebo-controlled study investigated the effects of oral morphine (0, 45, 135 mg/70 kg) and oral oxycodone (0, 15, 45 mg/70 kg) on buprenorphinemaintained opioid addicts. As a 3 : 1 morphine : oxycodone oral dose ratio yielded equivalent subjective and physiological effects in nondependent individuals, this ratio was used in the present study. Two self-administration laboratory procedures -that is, a drug versus money and a drug versus drug procedure -were assessed. Study participants (N = 12) lived in the hospital and were maintained on 4 mg/day sublingual buprenorphine. When participants chose between drug and money, money was preferred over all drug doses; only high-dose oxycodone was self-administered more than placebo. When participants chose between drug and drug, both drugs were chosen more than placebo, high doses of each drug were chosen over low doses, and high-dose oxycodone was preferred over high-dose morphine. The subjective, performance-impairing, and miotic effects of high-dose oxycodone were generally greater than those of high-dose morphine. The study demonstrated that a 3 : 1 oral dose ratio of morphine :
oxycodone was not equipotent in buprenorphinedependent individuals. Both self-administration procedures were effective for assessing the relative reinforcing effects of drugs; preference for one procedure should be driven by the specific research question of interest. 
Introduction
Currently, prescription pain relievers are among the most highly abused substances in the USA. The 2010 National Survey on Drug Use and Health report revealed that B2.0 million people in the USA reported initiating nonmedical use of prescription opioids, which was similar to the number of individuals initiating marijuana use (2.4 million). Among prescription opioids, oxycodone is one of the most commonly prescribed and most commonly abused (Schneider et al., 2009; Cicero et al., 2011) . It is an opioid analgesic used medically to treat moderate to severe pain and is marketed alone (Oxycontin) or in combination with other analgesics such as acetaminophen (Percocet) and aspirin (Percodan). Morphine, another commonly used analgesic, is considered by many to be the prototypical m-opioid agonist. It is the principal active ingredient in opium and is one of the oldest medications used to alleviate pain. For this reason, it is the m agonist against which other drugs in this class often are compared. Morphine is marketed under brand names such as Avinza, Kadian, MS Contin, and Roxanol.
Oxycodone and morphine are both strong opioids, but their potencies differ considerably depending on the route through which they are administered (Kalso, 2007; Boström et al., 2008) . For example, they are equipotent when administered intravenously for postoperative patient-controlled analgesia (Silvasti et al., 1998) and in studies assessing their abuse liability after intravenous administration (Comer et al., 2008; Stoops et al., 2010) . However, for postoperative pain relief, morphine is B10 times more potent than oxycodone when both medications are administered epidurally (Backlund et al., 1997) . In contrast, for treating cancer pain, morphine is B1.5-2 times less potent than oxycodone when both drugs are administered orally (Mercadonte and Caraceni, 2011) . Studies comparing the abuse liability of morphine and oxycodone after oral administration are generally lacking, which is surprising given that this is a highly relevant concern from a public health perspective. We found only one publication (Zacny and Lichtor, 2008) that directly compared the abuse liability of morphine and oxycodone after oral drug administration, which reported a potency ratio of 3 : 1 in producing miosis in nonopioid-dependent research volunteers. Although the overall subjective effect profiles of the two drugs were similar and, as with miosis, both had a potency ratio of 3 : 1, 20 mg oxycodone produced more abuse liability-related effects and fewer aversive effects than 60 mg morphine. However, neither drug functioned as a reinforcer, which was not entirely surprising given that the participants were nondrugabusing volunteers. Therefore, the authors suggested testing the psychopharmacological profiles of oxycodone and morphine in drug abusers, preferably those with a history of abusing prescription opioids.
The present study was conducted to meet two objectives. The first objective was to examine the effects of immediate-release oral oxycodone and morphine in opioid addicts. Participants were maintained on a fixed dose of sublingual buprenorphine to standardize the level of opioid dependence across participants and to avoid the emergence of opioid withdrawal symptoms, which would have confounded our results. From a clinical perspective, buprenorphine is approved by the US Food and Drug Administration to treat both pain and opioid use disorders, and the sublingual formulation is increasingly being used to treat patients with both problems. Thus, examining the abuse liability of morphine and oxycodone in participants maintained on sublingual buprenorphine increased the external validity of our study. The second objective was to compare directly a drug versus money and a drug versus drug self-administration choice procedure, to evaluate the advantages and disadvantages of each procedure. Subjective, performance, and physiological effects were examined to provide a more comprehensive profile of the relative pharmacodynamic effects of oxycodone and morphine in an opioiddependent sample.
Methods

Screening
After completing an initial telephone interview, eligible participants who endorsed daily opioid use came to the hospital and signed a screening consent form. A cutoff score of at least 10 was used to confirm the presence of physiological dependence on opioids (Wang et al., 1974) . Further inclusion criteria for the study were 21-45 years of age, normal body weight (within 20% of the body weight range specified for a given height according to the 1983 Metropolitan Life Insurance Height/Weight tables), and the ability to perform study procedures (verified in a practice session during the screening process). Exclusion criteria were sensitivity, allergy, or contraindication to opioids; current or a history of chronic pain; significant suicide risk; active hepatitis with SGOT or SGPT greater than three times the upper limit of normal; and pregnancy, lactation, birth, miscarriage or abortion within the previous 6 months. Individuals who were diagnosed with a current major Axis I disorder or who met Diagnostic and Statistical Manual of Mental Disorders, 4th ed. text revision criteria for dependence on drugs other than opioids, nicotine, or caffeine were also excluded from the study, as were those on parole or probation and those with a history of significant violent behavior. In addition, individuals requesting treatment for their drug use were excluded from the study and offered referrals to treatment.
Enrollment procedures
Before admission, all participants signed study consent forms that explained the overall aims of the study and described the risks and benefits of participation. A practice session familiarized participants with study tasks and procedures and ensured that they were capable of performing them during the study. Volunteers were housed on 5-South, a locked inpatient research unit of the New York State Psychiatric Institute. They were paid for study participation.
the drug were measured. Two different self-administration procedures, during which participants could choose between two reinforcers, were used during the study: a drug versus money procedure (Week 2) and a drug versus drug procedure (Weeks 3-8). Drugs and doses were administered in random order both within and across participants.
Throughout each experimental session, participants were seated in a room equipped with Macintosh computers that were connected to another computer in an adjacent room where experimenters continuously monitored their computer activities and behaviors. Vital signs monitors (Criticare Poet Plus 8100 vital signs monitor; Critical Systems Inc., Waukesha, Wisconsin, USA) were used to collect data on respiration [respiratory rate, SpO 2 (an estimate of arterial oxygen saturation), and end tidal CO 2 (expired carbon dioxide levels)] and cardiovascular function (heart rate, systolic pressure, and diastolic pressure).
Participants' physiological responses were monitored continuously throughout the experimental sessions. Baseline physiological measures were obtained and sufficient oxygen saturation (> 92%) was verified before drug administration. Participants wore a blood pressure cuff on the nondominant arm and were connected to a pulse oximeter. Supplemental oxygen at a constant flow rate of 2 l/min was provided through a nasal cannula for safety, as required by our Institutional Review Board. Pupil photographs were taken at designated time points ( During Week 2, drug administration occurred twice daily, once during a morning sample session at 11:00 h and once during an afternoon choice session at 16:00 h (if drug was chosen). One dose was tested each day from Monday to Friday (Table 1 ). During the sample session, participants were simultaneously given the drug and $20. During the choice session, they chose between these two options using a drug versus money self-administration task (see below). Throughout both sessions, subjective, performance, and physiological effects were measured before and at predetermined time points after drug administration ( Table 2 ).
The drug versus money self-administration task was completed during the choice session and then drug and/or money were delivered at time 0 (Table 2) . Participants chose between fractions of the money and the drug dose that they had received during the morning sample session. They were instructed to 'work' for all or part of the sampled dose or sampled money amount ($20) Session events: DEQ, Drug Effects Questionnaire; OSC, Opioid Symptom Checklist; performance, digit symbol substitution task, divided attention task, rapid information processing task, repeated acquisition of response sequences task; physiological monitoring, respiratory and cardiovascular monitoring initiated; pupil, pupil photograph taken; SOWS, Subjective Opioid Withdrawal Scale; VAS, Visual Analog Scale. b During week 2, sample sessions ended after the events were completed at 120 min; during weeks 3-8, the sample sessions were extended to 180 min to obtain a more complete assessment of the time course of drug effects. Choice sessions were similar to sample sessions except that the self-administration task was completed before drug administration. 506 Behavioural Pharmacology 2013, Vol 24 No 5&6 by making finger presses on a computer mouse. Ten choice trials were presented, and drug and money were available during each choice trial in 10% increments (i.e. if the dose for that day was 15 mg, during each trial participants could work for either 1.5 mg of drug or $2). Participants had to click the mouse a set number of times (the 'ratio requirement') to achieve either the drug or money increment. The ratio requirement for the drug and money options increased independently each time that option was selected. The initial requirement was 50 clicks on the mouse, and the ratio increased each time that option was selected (50, 100, 200, 400, 800, 1200, 1600, 2000, 2400, and 2800) . Thus, to receive the entire dose of the drug or all of the money available, the participant had to make 11 550 mouse clicks within 40 min. The fraction of drug earned during the choice session was administered at the end of the task; the fraction of money earned was added to total study earnings and disbursed upon study completion. Regardless of the participants' choices, the duration of the choice session remained the same during Week 2.
Weeks 3-8: drug versus drug
During Weeks 3-8, the drug was administered daily from Monday to Friday (Table 1) . Participants received a sample dose of drug at 11:00 h on Days 1 and 2 of each week (one session per day) and they were given the opportunity to self-administer the drug at 11:00 and 16:00 h (two sessions per day) on Days 3-5 (see below and Table 1) . One dose combination was tested each week. Subjective, performance, and physiological effects were measured before and at predetermined time points after drug administration (see Table 2 for session overview).
The drug versus drug self-administration task was completed and then the dose chosen (or nothing) was delivered at time 0 (Table 2) . Doses were identified with letters ('A' and 'B') and colored cups (red and blue). Participants were subsequently given the opportunity to choose verbally between 'dose A' and 'dose B', or they could choose 'neither' option. Participants then made 200 finger presses on the computer mouse. At the end of this 5-min task, the individual received whichever drug dose (or no dose) he/she had chosen. The six dose combinations were: placebo versus 45 mg/70 kg oxycodone, 15 versus 45 mg/70 kg oxycodone, placebo versus 135 mg/70 kg morphine, 45 versus 135 mg/70 kg morphine, 15 mg/70 kg oxycodone versus 45 mg/70 kg morphine, and 45 mg/70 kg oxycodone versus 135 mg/70 kg morphine. The total duration of the choice sessions during weeks 3-8 was the same regardless of the participants' choices.
Experimental measures Subjective effects
Subjective effects were measured using four questionnaires (for a more detailed description, see Comer et al., 1999) .
Participants completed (i) a visual analog scale (VAS), (ii) a drug effects questionnaire (DEQ), (iii) an opioid symptom checklist, and (iv) a subjective opioid withdrawal scale (SOWS). The VAS included questions about the individual's mood state, quality of the dose just received, and drug craving (for heroin, cocaine, alcohol, and tobacco). Participants rated each item by marking along a 100-mm line from 'not at all' (0 mm) to 'extremely' (100 mm). One item on the VAS asked participants to rate the monetary value of the dose, ranging from $0 (0 mm) to $20 (100 mm). The DEQ consisted of six questions used to rate drug effects and drug liking. The series of possible answers ranged from 0 (no good/bad effects at all) to 4 (very strong effects), and from -4 (dislike very much) to 4 (like very much). The opioid symptom checklist consisted of a series of 13 true/false questions (e.g. 'I feel like I am nodding') presented to measure prototypic opioid effects. Scores on the opioid symptom checklist could range between 0 and 12 (one point was added to the sum score for each 'true' answer, but if participants answered 'true' to the item 'I feel normal', one point was subtracted from the sum score). The SOWS was a 16-item questionnaire in which participants rated different withdrawal symptoms on a scale from 0 to 4 (0 being 'not at all', 4 being 'extremely'). SOWS sum scores could range between 0 and 64, with higher scores indicating higher levels of opioid withdrawal symptoms.
Performance effects
Participants completed computerized task batteries throughout the laboratory sessions. The battery consisted of four tasks: a 3-min digit-symbol substitution task used to assess changes in psychomotor skill, a 10-min divided attention task used to assess vigilance, a 10-min rapid information processing task used to assess information processing, and a 3-min repeated acquisition of response sequences task used to assess learning and memory (Comer et al., 1999) .
Physiological effects
Pupil diameter was measured at various time points throughout each session. Respiration was recorded every minute and measured as respiratory rate (breaths/min), an indirect measure of arterial oxygen saturation (SpO 2 ; %), and an indirect measure of expired CO 2 (end tidal CO 2 ; mmHg). Heart rate (beats/min), systolic blood pressure (mmHg), and diastolic blood pressure (mmHg) were automatically recorded every 5 min.
Drugs and doses
Test drugs included placebo, oxycodone (15 and 45 mg/70 kg), and morphine (45 and 135 mg/70 kg), which were administered orally during laboratory sessions. In addition, participants were maintained on 4 mg sublingual buprenorphine throughout the study.
Oxycodone hydrochloride (20 mg/ml) was purchased from Purdue Pharma L.P. (Ardsley, New York, USA). Morphine
Reinforcing effects of oxycodone and morphine Comer et al. 507 sulfate (20 mg/ml) was purchased from Cardinal Distribution Company (Syracuse, New York, USA). Solutions were mixed in an orange-flavored drink with 1 ml of peppermint oil floated on top to mask the taste of the drug; a total volume of 200 ml was administered at each dosing. Buprenorphine tablets were obtained from the National Institute on Drug Abuse through the Research Triangle Institute. Buprenorphine was chosen over other possible maintenance agents such as methadone because opioid-dependent patients medicated with buprenorphine are comparably more reality-oriented and clearheaded (Fischer et al., 1999) , which is advantageous for completing neuropsychological tests and laboratory sessions. The oxycodone doses were chosen on the basis of pilot work conducted in our laboratory, showing them to be pharmacologically active and well tolerated. The morphine doses were chosen for comparison, with a previous study demonstrating that a 3 : 1 potency ratio between oral morphine and oral oxycodone produced equivalent miotic effects in healthy nonopioid-dependent volunteers (Zacny and Lichtor, 2008) .
Statistical analyses
Repeated-measures analyses of variance were used to analyze the data for the drug versus money comparisons. Breakpoint values (the highest ratio values completed for drug and for money), percentage of trials chosen for drug and money, and amount of drug and money delivered were analyzed. Paired t-tests were used for the drug versus drug comparisons to analyze the average percentage of each option chosen (dose A, dose B, neither) during the six choice sessions for each dose combination. Planned comparisons were made between each active dose and placebo, between the active doses of each drug to assess dose dependency, and between the two low and two high doses of the drug to explore differences between morphine and oxycodone. Subjective, performance, and physiological effects were analyzed using repeatedmeasures analyses of variance. Both peak (or trough) and time-course data were examined. For peak/trough data, only data points after drug administration were assessed. Peak effects were analyzed for most of the measures, but trough effects were analyzed for certain measures if they reflected drug-induced responses more accurately (e.g. miosis). For time-course data, effects before and after drug administration were assessed. Comparisons with a P-value of 0.05 or less were considered statistically significant.
Results
Participants
Twelve participants (11 men, one woman; four Hispanic, four Black, three White, one Native American) completed the study. On average, participants were 40±3 years of age (range: 34-45 years) and had used heroin for 18±7 years (range: 7-25 years). All participants reported current use of heroin and spent an average of $70 per day on it (range: $25-125). Participants also reported current (within the past 30 days, n = 8) or previous (n = 12) recreational use of prescription opioids. The most commonly used prescription opioid was oxycodone (n = 11), although use of codeine (n = 6), morphine (n = 5), hydrocodone (n = 3), meperidine (n = 3), hydromorphone (n = 2), and fentanyl (n = 1) was also reported. Methadone and buprenorphine were used occasionally by all of the participants, but use of these drugs was primarily for alleviation of withdrawal symptoms. Typically, the prescription opioids were ingested orally, although some participants also reported intravenous or intranasal use. In addition, all participants smoked tobacco cigarettes (1/2-2 packs/day), four drank alcohol (one each drank alcohol 2, 4, 8, and 12 times per month), six used cocaine (three, once per month; two, twice per month; and one, eight times per month), and two used marijuana (once and three times per week respectively). Six additional participants dropped out of the study; two discontinued because they did not like being confined to the inpatient unit, one was dropped because of an outstanding warrant, and three were administratively discharged for noncompliance with unit policies.
Self-administration Drug versus money (Week 2)
During all choice sessions, breakpoint values for money (range: 1417-2333) were higher than for drug (range: 133-942; Fig. 1, top panels) . The high dose of oxycodone was the only active drug dose that differed significantly from placebo in both drug and money progressive ratio breakpoint values (P r 0.05). In addition, breakpoint values for the low and high doses of oxycodone were significantly different from one another (for money and drug: P r 0.01). However, breakpoint values did not significantly differ when oxycodone was compared with morphine.
During all choice sessions, the percentages of choices for money (range: 58-88%) were higher than for drug (range: 8-40%; Fig. 1, middle panels) . The high dose of oxycodone was also the only active drug dose that differed significantly from placebo in the percentage of choices for both drug and money (P r 0.05). The percentages of choices for the low and high doses of oxycodone also significantly differed from one another (P r 0.01). However, the percentages of drug and money that were self-administered did not differ significantly between oxycodone and morphine.
When 135 mg/70 kg morphine was available, participants self-administered 41 mg drug (Fig. 1, bottom panels ; 30% of the available dose) and when 45 mg/70 kg oxycodone was available, participants self-administered 21 mg drug (47% of the available dose). The amounts of morphine and oxycodone that were self-administered did not differ significantly, although the amount of high-dose morphine that was self-administered differed significantly from placebo (P r 0.001) and from the low dose of morphine (P r 0.01). In contrast, the amount of high-dose oxycodone that was self-administered did not significantly differ from placebo (P = 0.053) or the low dose of oxycodone (P = 0.068), although the difference approached statistical significance. The amount of money self-administered when the high dose of oxycodone was available ($11.50) was considerably lower than that when placebo was available ($16.67; P r 0.05) and when lowdose oxycodone was available ($17.50; P r 0.01). However, the amount of money that was self-administered when high-dose oxycodone was available did not differ significantly from the amount of money self-administered when high-dose morphine was available.
Drug versus drug (Weeks 3-8)
The high doses of both oxycodone and morphine were chosen significantly more often than placebo (Fig. 2 , top panels) and the respective low doses (Fig. 2 , middle panels). No significant preference emerged between the low morphine and oxycodone doses (Fig. 2 , bottom panels). However, the high dose of oxycodone was chosen more frequently than the high dose of morphine (79 vs. 15%, respectively; Fig. 2 , bottom panels).
Subjective effects Visual analog scale
Peak: The high doses of oxycodone and morphine (OXY-45 and MOR-135) produced significantly greater effects than placebo in several mean peak VAS ratings (Table 3 ; Fig. 3 , upper panels). The high dose of oxycodone (OXY-45) frequently produced a significantly larger effect than the low dose (OXY-15), with the only exceptions being 'bad' and 'sedated'. In contrast, morphine produced smaller dose-related changes in VAS ratings. Although the absolute mean peak values were consistently higher for the high dose of morphine compared with the low dose, none of the differences were statistically significant. The high doses of each drug differed significantly from one another in mean peak VAS ratings of 'high', 'high quality', 'I would pay', 'like', and 'potent' (all P's r 0.05). In all cases, the high dose of oxycodone produced greater effects than the high dose of morphine.
Time Course: The dose Â time interaction was significant for ratings of 'good', 'high', 'high quality', 'I would pay', 'like', and 'potent' (all P values r 0.01, data not shown).
Relative to placebo, OXY-45 produced a significant increase in several VAS ratings, such as 'good', 'like', and 'potent' (all P values r 0.001), which peaked at different time points after dosing. For example, maximum ratings of 'good' and 'like' were reported 60 min after the dose was administered, whereas the maximum rating of 'potent' was reported 120 min after dosing. Ratings after administration of the high dose of morphine fell consistently below those after administration of the high dose of oxycodone; however, no clear time point at which maximum ratings occurred during the session could be identified.
Drug effects questionnaire
Peak: The high doses of oxycodone and morphine differed significantly from placebo in mean peak ratings of 'good', 'like', and 'take again' (Table 3 ; Fig. 3 , lower panels). The high dose of oxycodone produced significantly greater mean peak DEQ ratings than the low dose for 'good', 'like', 'strong', and 'take again' (Table 3 ; Fig. 3 , lower panels). Peak ratings after administration of the high dose of morphine differed from those after administration of the low dose only with regard to the desire to take the dose again. Interestingly, none of the comparisons between OXY-45 and MOR-135 on the DEQ were significantly different. As with the VAS, placebo produced the greatest 'bad' effects peak ratings, and it did not differ significantly from MOR-135, although the difference approached significance (P = 0.07). MOR-45, OXY-15, and OXY-45 all produced significantly lower scores than placebo for ratings of 'bad' effects (all P values r 0.05).
Time course: The dose Â time interaction was significant for DEQ ratings of 'good', 'like', 'strong', and 'take again' (all P values r 0.001; data not shown). Relative to placebo, the high dose of oxycodone produced a significant increase in DEQ ratings of 'good', 'like', 'strong', and 'take again' (all P values r 0.001). Similar results were obtained for the high dose of morphine compared with placebo ('good' and 'like': P r 0.01; 'strong' and 'take again': P r 0.05). Only ratings of 'take again' were significantly lower for high dose morphine compared with high dose oxycodone (P r 0.05). The time-course data for selected DEQ ratings were similar to those for the corresponding VAS ratings, with the high dose of oxycodone having the highest ratings 1-2 h after dosing (at 90 min for 'good', 'like' 'strong', and 'take again'; data not shown). The high dose of morphine did not appear to produce a distinct peak rating for 'good', 'like', 'strong', or 'take again'.
Opioid symptom checklist
Peak: The mean peak scores on the opioid symptom checklist were similar to the pattern of responses on the DEQ. Namely, ratings after administration of OXY-45 and MOR-135 were significantly greater than those after administration of placebo (P r 0.01), and OXY-45 produced effects that were significantly greater than those produced by OXY-15 (P r 0.05), but the effects of the high doses of oxycodone and morphine were not significantly different from each other.
Time course: In contrast to the VAS and DEQ, the time to peak effects on the OSC was 15 min after administration of high-dose oxycodone (score = 3.0, data not shown). Ratings were similar 15 min (score = 2.3) and 60 min (score = 2.5) after administration of high-dose morphine. Thus, the high doses of both morphine and oxycodone produced maximal or near-maximal effects within 15 min, indicating that participants were able to detect opioid effects soon after dose administration.
Subjective opioid withdrawal scale
The SOWS score after placebo administration was significantly greater than those after administration of all four active doses of drug (MOR-45, MOR-135, and OXY-15 vs. placebo: P r 0.05; OXY-45 vs. placebo: P r 0.01; Table 3 ). There were no significant differences between the low and high doses of each drug, or between the high dose of morphine and the high dose of oxycodone. 
Physiological effects Pupil diameter
Trough: All four active doses of drug produced significant decreases in the mean trough pupil diameter compared with placebo (Fig. 4, top panel) . The high dose of oxycodone produced the lowest mean trough value, which was significantly different from the effects of placebo (P r 0.001), the low dose of oxycodone (P r 0.001), and the high dose of morphine (P r 0.01). Trough pupil diameter did not significantly differ for the two active doses of morphine.
Time course: Examination of the time course of changes in pupil diameter revealed a significant dose Â time interaction (P r 0.001; Fig. 4 , lower panel). Both doses of morphine and the high dose of oxycodone decreased pupil diameter significantly more than placebo (P r 0.01). Pupil diameters after administration of the two active doses of morphine did not differ significantly from each other. However, the high dose of oxycodone produced a smaller pupil diameter than the low dose of oxycodone and the high dose of morphine (P r 0.01). Minimal values for pupil diameter were observed 60 min after administration of the high dose of oxycodone and 90 min after administration of the high dose of morphine, demonstrating that the maximal miotic effects of morphine occurred later than those of oxycodone.
Respiration
Respiratory rate: Trough respiratory rate (data not shown) was significantly lower for the high dose of oxycodone (OXY-45 = 10.47 breaths/min) compared with placebo (11.21 breaths/min; P r 0.05) and the low dose of oxycodone (OXY-15 = 11.36 breaths/min; P r 0.05). However, trough respiratory rates did not differ between placebo and the low dose of oxycodone or either dose of morphine (MOR-45 = 11.27 breaths/min; MOR-135 = 10.98 breaths/ 
Select mean (±1 SEM) peak subjective ratings completed during sample sessions. Upper panels: peak ratings on the Visual Analog Scale as a function of drug and dose. Lower panels: peak ratings on the Drug Effects Questionnaire as a function of drug and dose. PBO, placebo; MOR-45, 45 mg/70 kg morphine; MOR-135, 135 mg/70 kg morphine; OXY-15, 15 mg/70 kg oxycodone; and OXY-45, 45 mg/70 kg oxycodone. *Significant difference from placebo; w significant difference between the low and high doses; } significant difference between high-dose morphine and high-dose oxycodone. One symbol, P r 0.05; two symbols, P r 0.01; three symbols, P r 0.001. min). Further, trough respiratory rates after the administration of the high dose of oxycodone did not differ significantly from those after the administration of the high dose of morphine. Examination of the time course of changes in the respiratory rate (Fig. 5, top panel) revealed that the maximal decreases in respiratory rates for the two high doses of drug were similar and occurred B120 min after dose administration. Likewise, the respiratory rates for the two lower doses of drug were similar.
End tidal CO 2 :. Peak end tidal CO 2 (data not shown) was significantly higher after administration of both high doses of drug (MOR-135 = 42.06 mmHg, OXY-45 = 41.90 mmHg) compared with placebo (40.18 mmHg; P < 0.001). A doseresponse relationship was observed for both morphine (P r 0.05) and oxycodone (P r 0.01), with the higher doses increasing end tidal CO 2 more than lower doses. However, effects of the high doses of morphine and oxycodone did not The mean trough and time course of pupil diameter changes during sample sessions. The upper panel shows trough diameters (mean±1 SEM) as a function of drug and dose. *Significant difference from placebo; w significant difference between the low and high doses; } significant difference between high-dose morphine and high-dose oxycodone. One symbol, P r 0.05; two symbols, P r 0.01; three symbols, P r 0. (Fig. 5, bottom panel) , however, revealed that the maximal decreases occurred B60-120 min after administration of OXY-45 and MOR-135.
Blood pressure and heart rate Systolic and diastolic pressure: No statistically significant changes were observed in trough systolic or diastolic blood pressure as a function of drug dose. When examined as a function of time, both systolic and diastolic pressures significantly decreased over the course of the laboratory session (P r 0.001 and P r 0.05, respectively; from B122/70 to 115/67 mmHg); however, neither systolic nor diastolic pressure changed as a function of dose.
Heart rate: Similar to blood pressure, few changes were observed in trough heart rate, with the exception of a small but statistically significant increase that occurred after administration of the high dose of morphine (65.5 beats/min) compared with placebo (62.8 beats/min; P r 0.05). Similar to blood pressure, heart rate decreased significantly across the session (P r 0.001; from B81 to 67 beats/min), but it did not change as a function of dose (data not shown).
Performance effects Rapid information task
The mean peak number of correct identifications of three consecutive odd or even numbers was significantly lower after administration of the high dose of oxycodone (213) compared with placebo (226; P r 0.05) and the low dose of oxycodone (227; P r 0.05). In addition, the number of correct identifications after administration of the high dose of oxycodone was significantly lower than that after administration of the high dose of morphine (229; P r 0.05). In contrast, the number of false alarms was significantly lower after administration of the high dose of oxycodone (92) compared with the low dose of oxycodone (125; P r 0.05). The number of correct identifications did not vary significantly across sessions, but the number of false alarms increased significantly (P r 0.001, data not shown).
Divided attention task
Performance on the divided attention task was also impaired by the high dose of oxycodone. As the speed of the tasks was adapted to the participants' accurate reaction, it directly reflected the participants' performance. The maximum speed in the task was significantly lower after administration of the high dose of oxycodone (5.4 ticks) compared with the low dose of oxycodone (5.9 ticks; P r 0.05) and placebo (6.1 ticks; P r 0.01). The maximum speed after administration of the high dose of oxycodone was also significantly lower than that after administration of the high dose of morphine (6.0 ticks; P r 0.05). In addition, the maximum speed decreased significantly across time (P r 0.002).
Repeated acquisition of response sequences task
Similar to results on the other tasks, the high dose of oxycodone produced impairments on the repeated acquisition of response sequences task, which requires participants to learn a 10-sequence pattern of responding on four individual computer keys. The number of patterns attempted was significantly lower after administration of the high dose of oxycodone (14.6) compared with the low dose of oxycodone (18.4; P r 0.05) and placebo (17.8; P r 0.05). The number of patterns attempted was also lower after administration of the high dose of oxycodone compared with the high dose of morphine (18.1; P r 0.05).
Discussion
Overall, these data suggest that a 3 : 1 morphine : oxycodone potency ratio cannot be assumed for pharmacodynamic effects in buprenorphine-dependent individuals. Moreover, although subjective, performance, and reinforcing effects were generally consistent with effects on miosis, they did not necessarily reflect other physiological effects, such as respiration. With regard to drug preference, when high-dose morphine and high-dose oxycodone were compared directly, participants exhibited a clear preference for oxycodone. However, because the high dose of oxycodone also produced greater miotic effects compared with the high dose of morphine, it is not possible to conclude that oxycodone has greater reinforcing effects compared with morphine. In fact, drug preference did not differ for the low doses of each drug, which produced similar subjective, performance, and miotic effects.
The two self-administration procedures produced generally similar patterns of effects, but each procedure had certain strengths and weaknesses. In the drug versus drug choice sessions, participants consistently preferred the high dose over the low dose of each drug and the high doses of each drug compared with placebo. When the high doses of morphine and oxycodone were compared directly, participants strongly preferred oxycodone. When using the drug versus money choice procedure, participants self-administered money more than either drug.
When active drug was compared with placebo, only the high dose of oxycodone produced a breakpoint value that was significantly greater than that for placebo, but the breakpoint values for the high doses of each drug did not significantly differ from one another. These findings suggest that both procedures were useful in providing evidence that high-dose oxycodone was preferred over high-dose morphine. The advantage of the drug versus drug procedure was that it was more sensitive to dose effects. However, this procedure is time consuming in that several weeks of testing were required to obtain this finding. The drug versus money procedure was less sensitive to dose compared with the drug versus drug procedure; however, it had the advantage of providing evidence that an alternative nondrug reinforcer (money) was preferred over both drugs and that participants were not willing to expend much effort to obtain the drugs. One potential problem with both procedures is that carryover effects from a previous dose could have altered subsequent decisions to self-administer drugs. We previously investigated potential carry-over effects from sample to choice sessions (Comer et al., 1999 (Comer et al., , 2001 ) and found that there were generally no changes in drug self-administration unless very high drug doses were administered (Comer and Collins, 2002) . In the present study, the doses of oxycodone and morphine that were tested could be considered low to moderate, on the basis of the physiological responses that we observed; hence, carryover effects were probably not a major factor in the selfadministration outcomes. Another potential problem with comparing the two self-administration procedures in the present study is that the order of testing the procedures was not randomized (i.e. the drug vs. money procedure was always tested first). In our experience, however, earlier dose exposures generally result in greater self-administration and more robust subjective responses, especially with placebo administration. The outcome in the present study was that participants self-administered far less drug in the drug versus money procedure than in the drug versus drug procedure; thus, order effects may not have been prominent in the present study. Nevertheless, a stronger experimental design would have used a random order of testing of the two self-administration procedures. In sum, both procedures were useful in examining the reinforcing effects of different drugs and doses, and the decision to use one procedure over another should be driven by the specific research question of interest. The data presented also highlight the importance of assessing physiological endpoints, such as miosis and respiration, which are critical for interpreting the measures of abuse liability (namely, subjective and reinforcing effects).
One factor to be taken into consideration when interpreting the present results is that the peak subjective ratings were fairly low overall compared with those in previous studies conducted in our laboratory, in which intranasal or intravenous opioids were administered to opioid abusers (Comer et al. 1997 (Comer et al. , 2008 . Further, the morphine doses used in the present study were low compared with those administered by opioid-dependent individuals on average when they are in the field; thus, the study participants could have been less motivated to work hard for a dose that represents only a small proportion of what they are accustomed to using. Another factor that may have contributed to the low subjective ratings was that all of the participants were accustomed to using heroin daily through the intranasal and/or intravenous routes; hence, although they reported abusing prescription opioids orally, they apparently did not find the effects produced by oral morphine and oxycodone in our study to be particularly robust. This finding may be partly because of the effects of interactions of oxycodone and morphine with buprenorphine. For these reasons, it is important to note that the present results may not be fully generalizable or applicable to other populations of opioid users (e.g. nondependent recreational prescription opioid abusers). However, we opted to maintain participants in our study on buprenorphine to minimize withdrawal symptoms (e.g. runny nose, vomiting, fatigue, insomnia, irritability, anxiety; Collins and Kleber, 2004) and increase the external validity of our study. That is, from a public health perspective, an increasing number of patients with chronic pain are abusing prescription opioids and clinicians are opting to use sublingual buprenorphine to treat both disorders (Heit and Gourlay, 2008; Manubay et al., 2011; Weiss et al., 2011; Barry et al., 2012) .
Because oxycodone and morphine did not produce similar miotic effects, it was not possible to determine whether the differences in subjective and reinforcing effects obtained with the high doses of each drug reflected differences between oxycodone and morphine or simply nonequivalence in the doses used. Ideally, we would have tested equimiotic effects of both drugs to examine differences in abuse liability between oxycodone and morphine. Future studies should be conducted on larger samples with differing doses of morphine and oxycodone to determine more conclusively equivalent dose ratios for different effects in populations with substance use disorders. Studies claiming high external validity for their results should also take the average doses used in 'the real world' into account when testing and comparing different doses of opioids. Nevertheless, the results of the present study were informative in demonstrating the myriad methodological issues that should be considered when examining the abuse liability of opioid medications.
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